act-539313
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 16, 2021 (NCT04753164)
Timeline
Indications
Mechanism of action
- Orexin receptor 1ANTAGONIST
HCRTR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05254548 | Phase 1 | Feb 18, 2022 | Idorsia Pharmaceuticals Ltd. |
| NCT04753164 | Phase 2 | Feb 16, 2021 | Idorsia Pharmaceuticals Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1